HC Wainwright Reiterates Neutral Rating for Lyell Immunopharma (NASDAQ:LYEL)

Lyell Immunopharma (NASDAQ:LYEL)‘s stock had its “neutral” rating restated by analysts at HC Wainwright in a research note issued on Thursday, MarketBeat Ratings reports. They presently have a $1.00 price target on the stock, down from their previous price target of $6.00. HC Wainwright’s target price points to a potential downside of 31.03% from the company’s previous close.

Lyell Immunopharma Trading Up 5.1 %

Shares of NASDAQ:LYEL opened at $1.45 on Thursday. The stock has a market capitalization of $369.66 million, a PE ratio of -1.61 and a beta of -0.40. Lyell Immunopharma has a 1 year low of $1.18 and a 1 year high of $3.41. The firm has a fifty day moving average price of $2.39 and a 200 day moving average price of $2.24.

Lyell Immunopharma (NASDAQ:LYEL) last issued its quarterly earnings data on Monday, May 6th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.04). Lyell Immunopharma had a negative return on equity of 33.92% and a negative net margin of 335,794.09%. On average, sell-side analysts forecast that Lyell Immunopharma will post -0.85 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Lyell Immunopharma

A number of large investors have recently bought and sold shares of LYEL. Opaleye Management Inc. acquired a new position in Lyell Immunopharma during the 1st quarter worth $7,482,000. Invenomic Capital Management LP lifted its position in Lyell Immunopharma by 16.8% during the 1st quarter. Invenomic Capital Management LP now owns 871,525 shares of the company’s stock worth $1,944,000 after acquiring an additional 125,110 shares during the last quarter. Jacobs Levy Equity Management Inc. acquired a new position in Lyell Immunopharma during the 1st quarter worth $64,000. Caxton Associates LP lifted its position in Lyell Immunopharma by 359.1% during the 1st quarter. Caxton Associates LP now owns 174,657 shares of the company’s stock worth $389,000 after acquiring an additional 136,611 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD lifted its position in Lyell Immunopharma by 1.4% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 6,731,477 shares of the company’s stock worth $15,013,000 after acquiring an additional 92,594 shares during the last quarter. 66.05% of the stock is currently owned by institutional investors.

About Lyell Immunopharma

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.